← Back

CalciMedica, Inc. Common Stock

CalciMedica, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate, Auxora, is an intravenous small molecule CRAC channel inhibitor being developed for acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, and severe COVID-19 pneumonia. The company also develops Auxora for ulcerative colitis, traumatic brain injury, and allergic asthma, as well as oral CRAC channel inhibitors for chronic inflammatory and immunologic diseases. CalciMedica is based in La Jolla, California.

Country

USA

Sector

Biotechnology

Price · split & dividend adjusted

News & notes moving CALC

CALC▼

CalciMedica Q2 GAAP EPS misses estimates by $0.16

CalciMedica reported a second-quarter GAAP loss of $0.45 per share, missing analyst estimates by $0.16. Cash and cash equivalents stood at $18.6 million as of June 30, 2026, which the company expects will fund operations into the second half of 2027. Research and development expenses fell to $2.1 million from $4.1 million in the same period last year.

CALC ▼

Seeking Alpha·38dRead more →